IASLC pleased by FDA approval of blood test to detect mutations in lung cancer

June 08, 2016

DENVER - The International Association for the Study of Lung Cancer (IASLC) praises the U.S. Food and Drug Administration's (FDA) decision to approve the first blood test to detect an oncogenic driver mutation in non-small cell lung cancer (NSCLC). This marks a significant step forward in lung cancer treatment. The cobas EGFR Mutation Test v2 detects epidermal growth factor receptor (EGFR) gene mutations and the FDA approved a blood-based companion diagnostic for the EGFR tyrosine kinase inhibitor erlotinib (Tarceva).

Lung cancer is the leading cause of cancer-related deaths among men and women in the U.S. and around the world. According to the National Cancer Institute, U.S. doctors will diagnose an estimated 221,200 with lung cancer this year, and 158,040 will succumb to the disease. Lung cancer tumors can shed DNA into a patient's blood which means that testing a blood sample, sometimes called a "liquid biopsy," may detect specific mutations within the shed DNA.

Health providers perform most genetic tests for NSCLC through lung tissue samples. These procedures can be invasive and difficult for patients. A reliable blood test could replace the need for direct tissue samples. This new test may provide additional benefit to patients who may be too ill or are otherwise unable to provide a tumor specimen for EGFR testing. Current screening methods find EGFR mutations in approximately 10-20 percent of Caucasian NSCLC patients and more than 50 percent of Asian NSCLC patients, making it a promising target for precision therapy treatments.

"This is another example of how lung cancer serves as a role model for precision medicine. The rapid pace of scientific advances in the disease's treatment allows for new and novel therapies," said Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine, and CEO of the IASLC. "This new and less invasive test gives patients and their doctors more options to more effectively diagnose and treat lung cancer. It is our hope that we can perform many more genetic tests through blood samples in the future."

Doctors have used erlotinib to help lung cancer patients for more than 10 years. The FDA first approved it in 2004 to treat patients with locally advanced or metastatic NSCLC after the failure of at least one prior chemotherapy regimen. In 2013, the FDA approved erlotinib for first-line treatment of patients with metastatic NSCLC whose tumors harbor EGFR exon 19 deletions or L858R substitution mutations as detected by an FDA-approved test.
-end-
Read the FDA's news release about the approval: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm.

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit http://www.iaslc.org for more information.

International Association for the Study of Lung Cancer

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.